Paksoy Senol E, Tasdelen I, Balaban Adim S, Ozkaya G, Tolunay S
Bratisl Lek Listy. 2013;114(11):645-9. doi: 10.4149/bll_2013_138.
The aim of the present study was to investigate the possibility to predict the histopathological features of breast and metastatic lymph nodes and survey and prognosis of patients and likelihood of being a predictive factor for treatment by using Ki67 immunohistochemical stain.
95 patients who were admitted to Uludag University Medical Faculty, Department of General Surgery with a diagnosis of stage II-III breast cancer between dates May 1997 and December 2002 were retrospectively evaluated with respect to breast cancer related prognostic factors treatments and last-control related data. Ki67 immunohistochemical staining was performed to appropriate specimens using Streptavidin-biotin technique. Ki67 was reported as the proliferation index, and the number of stained nuclei were stated to be / 1000.
In the evaluation of the lymph node by univariate analysis, we ascertained that duration of survival is shorter above the 227 cut-off value for Ki67 proliferative index. Length of survival of patients with tumor Ki67 proliferative index below 141 and with no distant metastasis was established to be better. Ki67 proliferative index in the lymph node was detected to increase more with increasing histological and nuclear grade, estrogen and progesterone receptor negativity and at stage III.
Since numerous factors are effective on breast cancer, each patient and tumor behaves differently. A lot of prognostic factors are taken into account while treatment choice is determined. We may have information on the biological behavior of the tumor in patients who underwent sentinel lymph node biopsy or axillary dissection in staining with Ki67 pattern (Tab. 5, Fig. 3, Ref. 13).
本研究旨在探讨通过Ki67免疫组化染色预测乳腺及转移淋巴结组织病理学特征、患者的概况及预后以及作为治疗预测因素可能性的方法。
回顾性评估了1997年5月至2002年12月期间因II - III期乳腺癌诊断入住于乌鲁达大学医学院普通外科的95例患者,收集了与乳腺癌相关的预后因素、治疗情况及末次随访相关数据。采用链霉亲和素 - 生物素技术对合适的标本进行Ki67免疫组化染色。Ki67以增殖指数报告,染色细胞核数量以/1000表示。
单因素分析评估淋巴结时,我们确定Ki67增殖指数高于227临界值时生存时间较短。肿瘤Ki67增殖指数低于141且无远处转移的患者生存时间较长。检测发现,淋巴结中的Ki67增殖指数随组织学和核分级增加、雌激素和孕激素受体阴性以及III期而增加得更多。
由于众多因素对乳腺癌有影响,每个患者和肿瘤的表现都不同。在确定治疗方案时会考虑许多预后因素。在用Ki67模式染色时,对于接受前哨淋巴结活检或腋窝清扫的患者,我们可能会了解肿瘤的生物学行为(表5,图3,参考文献13)。